Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced today that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

 

These programs will leverage BIIR’s leading position in human immunology with particular focus on cancer vaccines, auto-immune disease diagnostics and treatment, proprietary platforms in biosignature[1] and antibody development, with a view at identifying new leads that could be in-licensed by Roche. A Joint Research Committee will determine the most promising projects in that context, to be funded by Roche over a three-year period.

 

BRI will retain sole responsibility for programs outside the jointly developed projects.